We have performed analyses using our disease model to determine the effectiveness and cost-effectiveness of aspirin for chemoprevention again EAC in patients with BE.  Additional analyses studied patient preferences for aspirin as chemoprevention in both patients with BE and for the prevention of colorectal cancer.